The organ preservation treatment market encompasses the sector of healthcare and biotechnology focused on the solutions, devices, and techniques used to maintain the viability and functional integrity of donor organs between retrieval and transplantation. It includes technologies such as static cold storage, hypothermic machine perfusion, and normothermic machine perfusion, which regulate temperature, oxygenation, and nutrient supply to minimize tissue damage and ischemia. This market serves hospitals, transplant centers, and organ procurement organizations handling heart, kidney, liver, lung, and pancreas transplants.
The global organ preservation market was valued at USD 0.1 billion in 2024 and reached USD 0.2 billion in 2025. It is projected to grow at a robust compound annual growth rate (CAGR) of 6.8%, hitting USD 0.3 billion by 2030.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=261269915
The organ preservation treatment market is primarily driven by the surging global prevalence of end-stage chronic diseases and organ failure, alongside an increasing volume of transplant procedures and expanding healthcare infrastructure. However, market growth is significantly restrained by high equipment and operational costs associated with advanced preservation solutions, strict regulatory approval processes, and complex logistical challenges in organ transport. Lucrative opportunities lie in the adoption of next-generation normothermic and hypothermic machine perfusion technologies, expanding healthcare investments in emerging markets across the Asia-Pacific and GCC regions, and ongoing research into bioengineered tissues and advanced anti-ischemic formulations. Despite these prospects, the market faces critical challenges including a persistent shortage of donor organs relative to patient demand, significant risk of ischemia-reperfusion injury, high cost barriers in developing regions, and competition from emerging alternative therapies such as artificial organs and xenotransplantation.
Target customers in the organ preservation treatment market primarily include institutional buyers such as transplant centers, hospitals, surgical clinics, and organ procurement organizations (OPOs), alongside transplant surgeons and clinical procurement teams who act as key decision-makers. These customers prioritize organ viability, extended ischemic times, procedural efficiency, and improved post-transplant patient outcomes, driving strong preference for advanced warm perfusion technologies, automated monitoring systems, and specialized preservation solutions over traditional cold storage. Purchasing behavior is heavily governed by strict clinical safety protocols, regulatory compliance, reimbursement policies, and evidence-based clinical outcomes, with institutions increasingly favoring integrated, service-supported solutions and long-term procurement agreements that streamline logistics and expand the pool of usable donor organs.
Market entry, expansion, and profitability in the organ preservation treatment market are heavily driven by stringent regulatory frameworks, continuous technological advancements, and high economic barriers. Regulatory bodies enforce strict clearance pathways and quality standards for perfusion systems and preservation solutions to ensure transplant safety, which can delay product commercialization and increase compliance costs. Technologically, the landscape is rapidly shifting from traditional static cold storage toward advanced normothermic and hypothermic machine perfusion devices equipped with real-time sensors for viability monitoring, requiring significant R&D investment to maintain market competitiveness. Economically, while the growing global demand for organ transplantation drives long-term market expansion, high initial equipment acquisition costs, expensive specialized consumables, and complex reimbursement landscapes present substantial barriers to widespread adoption, particularly in resource-constrained healthcare settings.
The organ preservation market is undergoing a major clinical shift from traditional static cold storage to advanced machine perfusion systems, particularly normothermic machine perfusion (NMP) and hypothermic machine perfusion (HMP). Emerging trends focus on ex-vivo organ care platforms—such as the Organ Care System (OCS)—that maintain organs in near-physiological states, embed sensors for real-time monitoring of viability, and allow targeted therapies prior to transplantation to expand the donor pool and salvage extended criteria grafts. Additionally, the adoption of novel anti-biofilm and specialized preservation solutions like Custodiol HTK and University of Wisconsin solutions, alongside digital tracking and favorable CMS reimbursement models, are accelerating commercial uptake. These trends are evolving rapidly, with high double-digit growth projected in the normothermic machine perfusion and ex-vivo transport segments (CAGRs of 10% to 15%), significantly outpacing the baseline growth of conventional cold storage methods.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=261269915
Technological innovations disrupting the organ preservation treatment market are centered on advanced ex vivo machine perfusion systems, digital monitoring technologies, and novel preservation media. The industry is seeing rapid adoption of hypothermic and normothermic machine perfusion (HMP and NMP), such as ex vivo lung and liver perfusion platforms, which circulate oxygenated, nutrient-rich fluids to extend viable organ storage windows, reduce ischemic-reperfusion injury, and assess marginal donor organs prior to transplantation. Furthermore, innovations are driven by smart cold-chain devices featuring real-time wireless tracking, GPS positioning, and continuous temperature monitoring to ensure chain-of-custody transparency during transit. Advanced biopreservation solutions, specialized anti-ischemic coatings, and AI-enabled predictive platforms for real-time organ viability assessment are also gaining significant momentum, transforming organ allocation and transplant workflows.
In the organ preservation treatment market, short-term trends are characterized by temporary surges in static cold storage supplies during seasonal donor volume spikes and initial, unvalidated hype surrounding basic consumer-level bio-preservation claims. Conversely, long-term structural shifts are firmly anchored in the transition to advanced dynamic machine perfusion technologies (such as normothermic and hypothermic machine perfusion), the integration of artificial intelligence for real-time graft viability assessment, and the expanding adoption of specialized bio-engineered preservation solutions. Driven by the global mandate to expand donor pools, reduce ischemic injury, and accommodate complex extended-criteria donor organs, these enduring shifts are permanently transforming organ transplantation from reactive preservation into a proactive, data-driven, and extended-viability care model.
Source:https://www.marketsandmarkets.com/Market-Reports/organ-preservation-market-261269915.html
